Loading...
XSHE
300122
Market cap4.01bUSD
Jul 10, Last price  
12.17CNY
1D
7.04%
1Q
-22.63%
Jan 2017
-26.11%
IPO
-33.71%
Name

Chongqing Zhifei Biological Products Co Ltd

Chart & Performance

D1W1MN
XSHE:300122 chart
P/E
—
P/S
3.25
EPS
—
Div Yield, %
7.04%
Shrs. gr., 5y
8.39%
Rev. gr., 5y
-10.02%
Revenues
8.96b
-65.64%
492,428,885590,335,676604,047,459737,313,591628,740,039760,326,497780,177,947800,937,516712,738,058445,947,1511,342,568,6325,228,307,72710,587,318,31115,190,366,23030,652,415,90638,264,011,33152,917,767,02826,069,711,3618,958,435,384
Net income
-14.72b
L
152,009,074190,051,259231,589,722256,788,078196,383,625215,045,381130,347,847148,003,993197,401,92732,520,316432,275,4061,451,366,5312,366,438,7383,301,326,83110,208,548,4577,538,999,7018,069,868,2062,018,478,516-14,723,152,849
CFO
5.17b
111,659,461141,584,417210,612,67454,190,253221,247,243112,891,820221,576,180161,388,660223,448,28389,954,889203,609,676585,590,1951,366,993,8303,496,688,9408,507,591,8171,989,033,1058,996,369,98105,167,319,683
Dividend
Dec 25, 20240.2 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Chongqing Zhifei Biological Products Co., Ltd. is a Chinese firm primarily engaged in the innovation, manufacturing, and commercialization of vaccines and other biological pharmaceuticals within the country. The company's establishment dates back to 2009, and its main operational base is located in Chongqing, China.
URL
http://www.zhifeishengwu.com/
IPO date
Sep 28, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT